Q-omics provides the consensus-scored RPL19 profile across patient tissues and cancer cell-line models. RPL19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL19 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL19 protein abundance shows 19,966 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where RPL19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL19 survival associations across molecular data types. RPL19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL19 RNA expression–survival associations across cancer types. High RPL19 expression shows unfavorable associations in KIRP, LIHC, ACC and HNSC, but favorable associations in BRCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL19 RNA expression.
This table summarizes RPL19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL19 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, COAD and CHOL. The KIRC box plot shows higher RPL19 RNA expression in tumor versus normal tissue (log2 FC = +0.849, t-test p < 0.001).
This table shows molecular features associated with RPL19 in patient tissues and cancer cell lines. In patient samples, RPL19 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
